Formation of mitoxantrone adducts in human tumor cells: Potentiation by AN-9 and DNA methylation

Oncology Research

Volumn 14, Issue 6, 2003, Pages 279-290

  Parker, Belinda S ^a   Rephaeli, Ada ^b   Nudelman, Abraham ^c   Phillips, Don R ^a   Cutts, Suzanne M ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

AN 9; Decitabine; DNA adducts; DNA methylation; Mitoxantrone

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELL DNA; FORMALDEHYDE; MITOXANTRONE; NOVATRONE; PIVALOYLOXYMETHYL BUTYRATE; PRODRUG;

ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA ADDUCT; DNA METHYLATION; DRUG ACTIVITY; DRUG DNA BINDING; DRUG EFFECT; DRUG POTENTIATION; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 2942562380     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504003773994815     Document Type: Article

References (51)

1. Cheng, C. C.; Zee-Cheng, R. K. The design, synthesis and development of a new class of potent antineoplastic anthraquinones. Prog. Med. Chem. 20:83-118; 1983.
2. Martel, C. L.; Gumerlock, P. H.; Meyers, F. J.; Lara, P. N. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat. Rev. 29:171-187; 2003.
3. Crown, J. Evolution in the treatment of advanced breast cancer. Semin. Oncol. 25(5 Suppl. 12):12-17; 1998.
4. Cripe, L. D.; Hinton, S. Acute myeloid leukemia in adults. Curr. Treat. Options Oncol. 1:9-17; 2000.
5. Boland, M. P.; Fitzgerald, K. A.; O'Neill L. A. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J. Biol. Chem. 275:25231-25238; 2000.
6. Lown, J. W.; Hanstock, C. C. High field 1H-NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)]. J. Biomol. Struct. Dyn. 2:1097-1106; 1985.
7. Panousis, C.; Phillips, D. R. DNA sequence specificity of mitoxantrone. Nucleic Acids Res. 22:1342-1345; 1994.
8. Reszka, K.; Hartley, J. A.; Kolodziejczyk, P.; Lown, J. W. Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Evidence for covalent binding of 14C-labeled drug. Biochem. Pharmacol. 38:4253-4260; 1989.
9. Dackiewicz, P.; Skladanowski, A.; Konopa, J. 32P-postlabelling analysis of adducts formed by mitoxantrone and ametantrone with DNA and homopolydeoxyribonucleotides after enzymatic activation. Chem. Biol. Interact. 98:153-166; 1995.
10. Mewes, K.; Blanz, J.: Ehninger, G.; Gebhardt, R.; Zeller, K. P. Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Res. 53:5135-5142; 1993.
11. Panousis, C.; Kettle, A. J.; Phillips, D. R. Oxidative metabolism of mitoxantrone by the human neutrophil enzyme myeloperoxidase. Biochem. Pharmacol. 48:2223-2230; 1994.
12. Panousis, C.; Kettle, A. J.; Phillips, D. R. Myeloperoxidase oxidizes mitoxantrone to metabolites which bind covalently to DNA and RNA. Anticancer Drug Des. 10:593-605; 1995.
13. Parker, B. S.; Cullinane, C.; Phillips, D. R. Formation of DNA adducts by formaldehyde-activated initoxantrone. Nucleic Acids Res. 27:2918-2923; 1999.
14. Parker B. S.; Cutts, S. M.; Cullinane, C.; Phillips, D. R. Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts. Nucleic Acids Res. 28:982-990; 2000.
15. Parker, B. S.; Cutts, S. M.; Phillips, D. R. Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG dinucleotides. J. Biol. Chem. 276:15953-15960; 2001.
16. Thorndike, J.; Beck, W. S. Production of formaldehyde from N5-methyltetrahydrofolate by normal and leukemic leukocytes. Cancer Res. 37:1125-1132; 1977.
17. Ebeler, S. E.; Hinrichs, S. H.; Clifford, A. J.; Shibamoto, T. Analysis of reactive carbonyls in the expired air of transgenic mice. Anal. Biochem. 205:183-186; 1992.
18. Rephaeli, A.; Rabizadeh, E.; Aviram, A.; Shaklai, M.; Ruse, M.; Nudelman, A. Derivatives of butyric acid as potential anti-neoplastic agents. Int. J. Cancer 49:66-72; 1991.
19. Kasukabe, T.; Rephaeli, A.; Honma, Y. An anti-cancer derivative of butyric acid (pivalyloxmethyl butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells. Br. J. Cancer. 75:850-854; 1997.
20. Cutts, S. M.; Rephaeli, A.; Nudelman, A.; Hmelnitsky, I.; Phillips, D. R. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 61:8194-8202; 2001.
21. Taatjes, D. J.; Gaudiano, G.; Resing, K.; Koch, T. H. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem. 40:1276-1286; 1997.
22. Taatjes, D. J.; Gaudiano, G.; Resing, K.; Koch, T. H. Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem. 39:4135-4138; 1996.
23. Fenick, D. J.; Taatjes, D. J.; Koch, T. H. Doxoform and daunoform: Anthracycline-formaldehyde conjugates toxic to resistant tumor cells. J. Med. Chem. 40:2452-2461; 1997.
24. Ehrlich, M. DNA methylation in cancer: Too much, but also too little. Oncogene 21:5400-5413; 2002.
25. Esteller, M.; Herman, J. G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol. 196:1-7; 2002.
26. Robertson, K. D.; Jones, P. A. DNA methylation: Past, present and future directions. Carcinogenesis 21:461-467; 2000.
27. Nudelman, A.; Ruse, M.; Aviram, A.; Rabizadeh, E.; Shaklai, M.; Zimrah, Y.; Rephaeli, A. Novel anticancer prodrugs of butyric acid. J. Med. Chem. 35:687-694; 1992.
28. Rabizadeh, E.; Shaklai, M.; Eisenbach, L.; Nudelman, A.; Rephaeli, A. Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9). Isr. J. Med. Sci. 32:1186-1191; 1996.
29. Rabizadeh, E.; Shaklai, M.; Nudelman, A.; Eisenbach, L.; Rephaeli, A. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Lett. 328:225-229; 1993.
30. Siu, L. L.; Von Hoff, D. D.; Rephaeli, A.; Izbicka, E.; Cerna, C.; Gomez, L.; Rowinsky, E. K.; Eckhardt, S. G. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Invest. New Drugs 16:113-119; 1998.
31. Patnaik, A.; Rowinsky, E. K.; Villalona, M. A.; Hammond, L. A.; Britten, C. D.; Siu, L. L.; Goetz, A.; Felton, S. A.; Burton, S.; Valone, F. H.; Eckhardt, S. G. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 8:2142-2148; 2002.
32. Aviram, A.; Zimrah, Y.; Shaklai, M.; Nudelman, A.; Rephaeli, A. Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line. Int. J. Cancer 56:906-909; 1994.
33. Vidali, G.; Boffa, L, C.; Bradbury, E. M.; Allfrey, V. G. Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc. Natl. Acad. Sci. USA 75:2239-2243; 1978.
34. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications. Nature 403:41-45; 2000.
35. Smith, P. J.; Morgan, S. A.; Fox, M. E.; Watson, J. V. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem. Pharmacol. 40:2069-2078; 1990.
36. Cutts, S. M.; Swift, L. P.; Rephaeli, A.; Nudelman, A.; Phillips, D. R. Sequence specificity of adriamycin-DNA adducts in human tumor cells. Mol. Cancer Ther. 2:661-670; 2003.
37. Maier, K. L.; Wippermann, U.; Leuschel, L.; Josten, M.; Pflugmacher, S.; Schroder, P.; Sandermann, H., Jr.; Takenaka, S.; Ziesenis, A.; Heyder, J. Xenobiotic-metabolizing enzymes in the canine respiratory tract. Inhal. Toxicol. 11:19-35; 1999.
38. Skladanowski, A.; Konopa, J. Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells. Br. J. Cancer 82:1300-1304; 2000.
39. Zimra, Y.; Nudelman, A.; Zhuk, R.; Rabizadeh, E.; Shaklai, M.; Aviram, A.; Rephaeli, A. Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis. J. Cancer Res. Clin. Oncol. 126:693-698; 2000.
40. Niitsu, N.; Kasukabe, T.; Yokoyama, A.; Okabe-Kado J.; Yamamoto-Yamaguchi, Y.; Umeda, M.; Honma Y. Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol. Pharmacol. 58:27-36; 2000.
41. Jones, K. H.; Liu, J. J.; Roehm, J. S.; Eckel, J. J.; Eckel, T. T.; Stickrath, C. R.; Triola, C. A.; Jiang, Z.; Bartoli, G. M.; Cornwell, D. G. Gamma-tocopheryl quinone stimulates apoptosis in drug-sensitive and multidrug-resistant cancer cells. Lipids 37:173-184; 2002.
42. Momparler, R. L.; Bovenzi, V. J. DNA methylation and cancer. Cell Physiol. 183:145-154; 2000.
43. Millard, J. T.; Beachy, T. M. Cytosine methylation enhances mitomycin C cross-linking. Biochemistry 32:12850-12856; 1993.
44. Johnson, W. S.; He, Q. Y.; Tomasz, M. Selective recognition of the m5CpG dinucleotide sequence in DNA by mitomycin C for alkylation and cross-linking. Bioorg. Med. Chem. 3:851-860; 1995.
45. Chen, J. X.; Zheng, Y.; West, M.; Tang, M. S. Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res. 58:2070-2075; 1998.
46. Weisenberger, D. J.; Romano, L. J. Cytosine methylation in a CpG sequence leads to enhanced reactivity with benzo[a]pyrene diol epoxide that correlates with a conformational change. J. Biol. Chem. 274:23948-23955; 1999.
47. Denissenko, M. F.; Chen, J. X.; Tang, M. S.; Pfeifer, G. P. Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc. Natl. Acad. Sci. USA 94:3893-3898; 1997.
48. Rhee, I.; Bachman, K. E.; Park, B. H.; Jair, K. W.; Yen, R. W.; Schuebel, K. E.; Cui, H.; Feinberg, A. P.; Lengauer, C.; Kinzler, K. W.; Baylin, S. B.; Vogelstein, B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552-556; 2002.
49. Parker, B. S.; Cutts, S. M.; Nudelman, A.; Rephaeli, A.; Phillips, D. R.; Sukumar, S. Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells. Cancer Biol. Ther. 2:259-263; 2003.
50. Cutts, S. M.; Parsons, P. G.; Sturm, R. A.; Phillips, D. R. Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J. Biol. Chem. 271:5422-5429; 1996.
51. Yang, A. S.; Issa, J. P. Mitoxantrone: A hypomethylating agent? Cancer Biol. Ther. 2:264-265; 2003.